Free tool
FAERS Monitor: Cosopt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020869 or its brand name (Cosopt, Dorzolamide Hydrochloride, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
5,768
Serious
3,918
68% of reports
Hospitalization
1,674
Death reported
342
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective501
- intraocular pressure increased324
- eye irritation321
- eye pain285
- glaucoma277
- fatigue239
- off label use230
- dyspnoea218
- ocular hyperaemia218
- fall212
- vision blurred206
- nausea195
- diarrhoea189
- asthenia187
- pain181
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 110 |
| 2005 | 118 |
| 2006 | 117 |
| 2007 | 165 |
| 2008 | 166 |
| 2009 | 191 |
| 2010 | 246 |
| 2011 | 271 |
| 2012 | 294 |
| 2013 | 330 |
| 2014 | 315 |
| 2015 | 359 |
| 2016 | 400 |
| 2017 | 391 |
| 2018 | 351 |
| 2019 | 363 |
| 2020 | 346 |
| 2021 | 205 |
| 2022 | 228 |
| 2023 | 216 |
| 2024 | 201 |
| 2025 | 244 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,391 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 324 | 94.8 | 85.2 | 29,242 |
| glaucomaSignal | 277 | 53.2 | 47.4 | 13,948 |
| eye irritationSignal | 321 | 20.4 | 18.4 | 5,900 |
| eye painSignal | 285 | 18.5 | 16.5 | 4,692 |
| ocular hyperaemiaSignal | 218 | 16.8 | 14.8 | 3,221 |
| vision blurredSignal | 206 | 5.5 | 4.8 | 753 |
| fallSignal | 212 | 2.3 | 2.0 | 161 |
| asthenia | 187 | 1.8 | 1.6 | 69 |
| dyspnoea | 218 | 1.4 | 1.2 | 26 |
| drug ineffective | 501 | 1.4 | 1.3 | 57 |
| fatigue | 239 | 1.1 | 1.0 | 3 |
| pain | 181 | 1.1 | 0.9 | 1 |
| diarrhoea | 189 | 1.1 | 0.9 | 1 |
| off label use | 230 | 1.0 | 0.8 | 0 |
| nausea | 195 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.